Pharmaceuticals

AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth

SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- AsymBio , a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary ofAsymchem Group (stock codes: 002821.SZ / 6821.HK), today announced a total capital injection of ...

2026-08-04 20:30 4019

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS  (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deplo...

2026-08-04 18:15 2294

Sisram Medical Powers Up China EBD Growth Engine with Flagship "黑金牛奶光" Launch

Driving Innovation and Proactive Empowerment to Unlock Localized Growth in China HONG KONG, Aug. 4, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"), injectables, and other complementary solutions, today un...

2026-08-04 17:37 3975

Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite

* Piramal Pharma Solutions has added a new spray drying suite with Band 5 containment capacity at its dedicated peptide facility in Turbhe, India, equipped with its own air handling units, nitrogen supply, and control systems. * The new suite empowers Turbhe to support the formulation of chall...

2026-08-04 17:08 2175

Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa

SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases, today announced that its Efsubaglutide alfa manufacturing facility in Suzhou has officially passed a compliance...

2026-08-04 13:25 3036

Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy

At the Precision Oncology Academy 2026, leading international experts explored how insights from tumour DNA and RNA can reveal treatment opportunities, explain drug resistance, and translate into more confident treatment decisions to improve cancer care. KUALA LUMPUR, Malaysia, Aug. 4, 2026 /PRN...

2026-08-04 06:00 15154

Enzene Launches NeX™, a Comprehensive Suite of Solutionsto Enable Cost-Efficient, High-Yielding Local Biomanufacturing

PUNE, India, Aug. 4, 2026 /PRNewswire/ -- Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO™), today announced the launch of NeX™, a transformative end-to-end partnership model that enables governments, institutions, and biopharma organizations to ...

2026-08-04 02:25 4104

KPJ Healthcare Launches First Orthopaedic and Rheumatology Centre of Excellence Under the KPJ Health System

BUKIT MERTAJAM, Malaysia, Aug. 4, 2026 /PRNewswire/ -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group") today launched its first Orthopaedic and Rheumatology Centre of Excellence ("CoE") at KPJ Penang Specialist Hospital ("KPJ Penang"), marking the third CoE under the KPJ Health System ("K...

2026-08-04 00:06 4168

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada. -Positive preclinical data in non-human primates announced for first-in-class once-da...

2026-08-03 18:55 3158

WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model

SHANGHAI, Aug. 3, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first half ending June 30, 2026 ("Reporting Period"). The Company...

2026-08-03 17:49 4637

New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS

* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL) ...

2026-08-02 22:01 3494

Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results

HANGZHOU, China, July 31, 2026 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its financial results for the fiscal year ended March 31, 2026. Mr. Frank Zhao, Interim ...

2026-07-31 20:30 8772

Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy

* RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases * RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to target p21 gene activation for long-lasting anti-fi...

2026-07-31 19:00 4559

IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand

SHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharmanovia, a global specialty pharmaceutical company which partners with innovative biotech and large pha...

2026-07-31 15:48 2675

CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial

HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting, CellOrigin's scientific co...

2026-07-31 14:15 2996

Kuching to Host Asia's Leading Diabetes Experts at "Diabetes Asia 2026" Conference (DAC 2026)

KUCHING, Malaysia, July 30, 2026 /PRNewswire/ -- As diabetes continues to place an increasing burden on Malaysia's healthcare system — affecting an estimated 4.75 million Malaysian adults - Kuching will become the regional meeting point for leading diabetes experts this October as it hosts the "D...

2026-07-30 22:15 3097

HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates

HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ -- HKeyBio has establishedHKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration Program. The p...

2026-07-30 21:06 2271

Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science

Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world "blind test" for frontier AI and foundation models, with a transparent public leaderboard. CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- As general-purpose and domain-spec...

2026-07-30 21:00 2674

NIPRO CORPORATION Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States

New medium-cutoff Dialyzer with a Super High-flux membrane brings NIPRO's approach to expanded hemodialysis to United States healthcare providers.  OSAKA, Japan, July 30, 2026 /PRNewswire/ -- NIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food ...

2026-07-30 20:10 2167

Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors

Business development and corporate strategy executive joins Board as Company advances its clinical programs and partnering activity BRADENTON, Fla., July 30, 2026 /PRNewswire/ -- Continuity Biosciences today announced the appointment of Vicky Papoutsis to its Board of Directors. Vicky brings mor...

2026-07-30 20:00 1459
1 ... 567891011 ... 346